Capricor Therapeutics, Inc.
CAPR
$30.24
-$0.66-2.15%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | 11.13M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | 11.13M |
| Cost of Revenue | 23.13M | 20.36M | 22.05M | 18.92M | 14.55M |
| Gross Profit | -23.13M | -20.36M | -22.05M | -18.92M | -3.42M |
| SG&A Expenses | 6.02M | 5.92M | 5.67M | 6.07M | 4.27M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 29.16M | 26.28M | 27.72M | 24.98M | 18.83M |
| Operating Income | -29.16M | -26.28M | -27.72M | -24.98M | -7.70M |
| Income Before Tax | -30.17M | -24.57M | -25.91M | -24.39M | -7.12M |
| Income Tax Expenses | 1.60K | -- | -- | -- | 1.60K |
| Earnings from Continuing Operations | -30.17M | -24.57M | -25.91M | -24.39M | -7.12M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -30.17M | -24.57M | -25.91M | -24.39M | -7.12M |
| EBIT | -29.16M | -26.28M | -27.72M | -24.98M | -7.70M |
| EBITDA | -28.65M | -25.79M | -27.23M | -24.58M | -7.32M |
| EPS Basic | -0.62 | -0.54 | -0.57 | -0.53 | -0.16 |
| Normalized Basic EPS | -0.39 | -0.34 | -0.35 | -0.33 | -0.10 |
| EPS Diluted | -0.62 | -0.54 | -0.57 | -0.53 | -0.16 |
| Normalized Diluted EPS | -0.39 | -0.34 | -0.35 | -0.33 | -0.10 |
| Average Basic Shares Outstanding | 48.85M | 45.72M | 45.71M | 45.64M | 44.51M |
| Average Diluted Shares Outstanding | 48.85M | 45.72M | 45.71M | 45.64M | 44.51M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |